TY - JOUR
T1 - Universal Definition and Classification of Heart Failure
T2 - A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure
AU - Bozkurt, Biykem
AU - Coats, Andrew JS
AU - Tsutsui, Hiroyuki
AU - Abdelhamid, Magdy
AU - Adamopoulos, Stamatis
AU - Albert, Nancy
AU - Anker, Stefan D.
AU - Atherton, John
AU - Böhm, Michael
AU - Butler, Javed
AU - Drazner, Mark H.
AU - Felker, G. Michael
AU - Filippatos, Gerasimos
AU - Fonarow, Gregg C.
AU - Fiuzat, Mona
AU - Gomez-Mesa, Juan–Esteban E.
AU - Heidenreich, Paul
AU - Imamura, Teruhiko
AU - Januzzi, James
AU - Jankowska, Ewa A.
AU - Khazanie, Prateeti
AU - Kinugawa, Koichiro
AU - Lam, Carolyn S.P.
AU - Matsue, Yuya
AU - Metra, Marco
AU - Ohtani, Tomohito
AU - Francesco Piepoli, Massimo
AU - Ponikowski, Piotr
AU - Rosano, Giuseppe M.C.
AU - Sakata, Yasushi
AU - SeferoviĆ, Petar
AU - Starling, Randall C.
AU - Teerlink, John R.
AU - Vardeny, Orly
AU - Yamamoto, Kazuhiro
AU - Yancy, Clyde
AU - Zhang, Jian
AU - Zieroth, Shelley
N1 - Publisher Copyright:
© 2021
PY - 2021/4
Y1 - 2021/4
N2 - In this document, we propose a universal definition of heart failure (HF) as the following: HF is a clinical syndrome with symptoms and or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and or objective evidence of pulmonary or systemic congestion. We propose revised stages of HF as follows. At-risk for HF (Stage A), for patients at risk for HF but without current or prior symptoms or signs of HF and without structural or biomarkers evidence of heart disease. Pre-HF (stage B), for patients without current or prior symptoms or signs of HF, but evidence of structural heart disease or abnormal cardiac function, or elevated natriuretic peptide levels. HF (Stage C), for patients with current or prior symptoms and/or signs of HF caused by a structural and/or functional cardiac abnormality. Advanced HF (Stage D), for patients with severe symptoms and/or signs of HF at rest, recurrent hospitalizations despite guideline-directed management and therapy (GDMT), refractory or intolerant to GDMT, requiring advanced therapies such as consideration for transplant, mechanical circulatory support, or palliative care. Finally, we propose a new and revised classification of HF according to left ventricular ejection fraction (LVEF). The classification includes HF with reduced EF (HFrEF): HF with an LVEF of ≤40%; HF with mildly reduced EF (HFmrEF): HF with an LVEF of 41% to 49%; HF with preserved EF (HFpEF): HF with an LVEF of ≥50%; and HF with improved EF (HFimpEF): HF with a baseline LVEF of ≤40%, a ≥10-point increase from baseline LVEF, and a second measurement of LVEF of >40%.
AB - In this document, we propose a universal definition of heart failure (HF) as the following: HF is a clinical syndrome with symptoms and or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and or objective evidence of pulmonary or systemic congestion. We propose revised stages of HF as follows. At-risk for HF (Stage A), for patients at risk for HF but without current or prior symptoms or signs of HF and without structural or biomarkers evidence of heart disease. Pre-HF (stage B), for patients without current or prior symptoms or signs of HF, but evidence of structural heart disease or abnormal cardiac function, or elevated natriuretic peptide levels. HF (Stage C), for patients with current or prior symptoms and/or signs of HF caused by a structural and/or functional cardiac abnormality. Advanced HF (Stage D), for patients with severe symptoms and/or signs of HF at rest, recurrent hospitalizations despite guideline-directed management and therapy (GDMT), refractory or intolerant to GDMT, requiring advanced therapies such as consideration for transplant, mechanical circulatory support, or palliative care. Finally, we propose a new and revised classification of HF according to left ventricular ejection fraction (LVEF). The classification includes HF with reduced EF (HFrEF): HF with an LVEF of ≤40%; HF with mildly reduced EF (HFmrEF): HF with an LVEF of 41% to 49%; HF with preserved EF (HFpEF): HF with an LVEF of ≥50%; and HF with improved EF (HFimpEF): HF with a baseline LVEF of ≤40%, a ≥10-point increase from baseline LVEF, and a second measurement of LVEF of >40%.
UR - http://www.scopus.com/inward/record.url?scp=85101869093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101869093&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2021.01.022
DO - 10.1016/j.cardfail.2021.01.022
M3 - Article
C2 - 33662581
AN - SCOPUS:85101869093
SN - 1071-9164
VL - 27
SP - 387
EP - 413
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 4
ER -